ArticleACS central science2025
Peptide and Protein Cyclization by a Promiscuous Graspetide Synthetase.
Article in ACS central science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- De Novo Discovery of Bioactive Cyclic Peptides via Cellular Selection of Genetically Encoded Libraries.Chembiochem : a European journal of chemical biology · 2026Review
- Repositioning the Leader Peptide in Graspetide Biosynthesis.Journal of the American Chemical Society · 2026Article
- A Versatile Enzymatic Pathway for Modification of Peptide C‑Termini.ACS central science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macrocyclic peptides have drawn considerable interest as modalities for drug discovery. Graspetides are a class of ribosomally synthesized and post-translationally modified peptides (RiPPs) that harbor one or more macrocycles. These macrocycles are built via side chain-side chain linkages that are installed by ATP-grasp enzymes, giving the peptide family their name. We recently reported on the discovery, structure, and biosynthesis of the graspetide pre-fuscimiditide which is comprised of a stem covalently linked by two ester moieties and a 10 aa loop. Here we probe the substrate tolerance of the fuscimiditide ATP-grasp enzyme, ThfB, and show that it is highly promiscuous. ThfB can cyclize substrates with substitutions to or extensions of the stem region as well as generate multivalent cyclic structures. ThfB also shows remarkable tolerance to substitutions in the loop of pre-fuscimiditide. Loops comprised of flexible glycine-serine sequences ranging from 4 aa to 72 aa were efficiently cyclized by ThfB. Even substrates in which full-length proteins were swapped for the 10 aa loop of pre-fuscimiditide could be cyclized by ThfB. We also show that ThfB can covalently cross-link supramolecularly assembled protein chains. These data show that ThfB is a highly generalizable biocatalyst for both peptide and protein macrocyclization as well for intermolecular protein cross-linking.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.